Franklin Biotechnology Discovery has an experienced team at the helm, but it needs to distinguish itself.
Franklin Biotechnology Discovery A FBDIX
- NAV / 1-Day Return 149.77 / +0.73 %
- Total Assets 949.0 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.070%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 36%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:12 PM GMT+0
Morningstar’s Analysis FBDIX
Will FBDIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Amgen Inc | 8.05 | 72.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.27 | 65.4 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 6.20 | 55.8 Mil | Healthcare |
Ascendis Pharma A/S ADR | 3.86 | 34.7 Mil | Healthcare |
Insmed Inc | 3.62 | 32.5 Mil | Healthcare |
Biogen Inc | 3.33 | 30.0 Mil | Healthcare |
Merus NV | 3.29 | 29.6 Mil | Healthcare |
Gilead Sciences Inc | 3.08 | 27.7 Mil | Healthcare |
AstraZeneca PLC ADR | 2.92 | 26.2 Mil | Healthcare |
Intra-Cellular Therapies Inc | 2.70 | 24.3 Mil | Healthcare |